🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 22 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/03/2022 | 237,46 | 242,50 | 235,05 | 235,54 | -1,31% | 3,14% | 1.548.000 |
| 04/03/2022 | 233,40 | 243,18 | 233,04 | 238,66 | +1,26% | 4,34% | 2.032.800 |
| 03/03/2022 | 234,93 | 238,53 | 234,74 | 235,69 | +0,67% | 1,61% | 1.140.600 |
| 02/03/2022 | 230,18 | 235,50 | 229,40 | 234,11 | +1,48% | 2,65% | 1.029.100 |
| 01/03/2022 | 229,19 | 232,52 | 228,50 | 230,69 | +0,29% | 1,75% | 1.253.800 |
| 28/02/2022 | 227,99 | 230,13 | 226,18 | 230,02 | -0,12% | 1,73% | 2.035.700 |
| 25/02/2022 | 229,46 | 233,16 | 228,04 | 230,30 | +0,02% | 2,23% | 1.428.100 |
| 24/02/2022 | 227,70 | 230,43 | 225,28 | 230,25 | -0,19% | 2,26% | 1.475.200 |
| 23/02/2022 | 231,70 | 233,53 | 229,20 | 230,69 | +0,21% | 1,87% | 1.817.100 |
| 22/02/2022 | 229,21 | 233,03 | 229,21 | 230,21 | +0,26% | 1,67% | 1.692.000 |
| 18/02/2022 | 233,00 | 233,89 | 228,55 | 229,61 | -1,36% | 2,29% | 1.271.200 |
| 17/02/2022 | 233,85 | 234,95 | 230,06 | 232,77 | -1,27% | 2,09% | 1.665.300 |
| 16/02/2022 | 233,46 | 236,89 | 231,56 | 235,77 | +1,01% | 2,28% | 1.402.200 |
| 15/02/2022 | 231,88 | 233,87 | 231,29 | 233,41 | +0,94% | 1,11% | 1.583.900 |
| 14/02/2022 | 233,75 | 234,00 | 229,26 | 231,23 | -1,14% | 2,03% | 1.578.100 |
| 11/02/2022 | 236,55 | 237,34 | 233,17 | 233,89 | -0,85% | 1,76% | 1.524.400 |
| 10/02/2022 | 238,39 | 241,01 | 234,46 | 235,89 | -3,42% | 2,75% | 1.809.500 |
| 09/02/2022 | 242,52 | 245,61 | 241,51 | 244,24 | +1,37% | 1,69% | 1.069.900 |
| 08/02/2022 | 242,36 | 243,00 | 239,23 | 240,94 | -0,95% | 1,56% | 1.135.700 |
| 07/02/2022 | 243,32 | 244,81 | 241,22 | 243,26 | +0,54% | 1,48% | 1.202.900 |
| 04/02/2022 | 241,27 | 244,63 | 238,48 | 241,96 | -0,73% | 2,55% | 1.822.400 |
| 03/02/2022 | 250,16 | 250,16 | 243,54 | 243,75 | -3,87% | 2,65% | 2.519.800 |
| 02/02/2022 | 243,58 | 254,93 | 241,00 | 253,57 | +3,22% | 5,72% | 3.679.900 |
| 01/02/2022 | 242,39 | 245,77 | 241,51 | 245,66 | +1,07% | 1,76% | 2.777.100 |
| 31/01/2022 | 240,87 | 244,41 | 239,16 | 243,05 | +0,01% | 2,18% | 2.829.000 |
| 28/01/2022 | 227,29 | 243,30 | 227,18 | 243,02 | +6,48% | 7,09% | 3.164.300 |
| 27/01/2022 | 228,99 | 233,69 | 226,89 | 228,22 | +0,72% | 2,97% | 2.237.000 |
| 26/01/2022 | 226,62 | 229,81 | 225,01 | 226,58 | -0,23% | 2,12% | 1.998.900 |
| 25/01/2022 | 226,09 | 229,63 | 223,66 | 227,11 | -1,12% | 2,64% | 1.956.300 |
| 24/01/2022 | 225,13 | 229,95 | 221,69 | 229,68 | +0,70% | 3,67% | 2.818.900 |